ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P33-19 New Medical, Medical Drug and Behavioral Health Policy Management Updates for Commercial & Medicare Advantage Lines of Business
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 01, 2019
လံာ်တီလံာ်မီတဖၣ်ဒီး လံာ်ကွီၣ်ဒိတဖၣ်အစၢတဖၣ်
တၢ်ပာ်ဖျါ 2081 - 2090 လၢ 3613 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P35-19 Appeals Policy for no Prior Authorization Effective June 3, 2019
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 01, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP30-19 Pharmacy Benefit Update – New Drug-Related Prior Authorization with Quantity Limit Criteria: Hereditary transthyretin-mediated (hATTR) Amyloidosis Neuropathy
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 27, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP33-19 SmartChoice Program for Fully Insured Commercial Products
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 27, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP32-19 Pharmacy Benefit Exclusion for Glyrx-PF, Libtayo, Lumoxiti, Onpattro, Poteligeo, and Xerava
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 27, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP34-19 Pharmacy Benefit Exclusion for Antineoplastic and Adjunctive Therapies
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 27, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP31-19 Change to Outpatient Therapies Prior Authorization Requirements for Medicare Advantage Subscribers
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 27, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP29-19 Pharmacy Benefit Update – New Drug-Related Prior Authorization with Quantity Limit Criteria: Arikayce
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 27, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP23-19 Reminder Payment Policy Auditing System
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 13, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP28-19 Interest Paid on Clean Claims
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 13, 2019